FibroBiologics, Inc. (FBLG:NASDAQ) closed at $0.924 on November 10, 2026, down 4.50% on the day. The stock trades 90.4% below its 52-week high of $9.60 and 49.0% above its 52-week low of $0.620. Over the past year, it lost 85.8%. FibroBiologics, Inc. is part of the Transportation sector.
In 252 trading sessions since November 10, 2025, FBLG closed higher on 105 days (42%). Its best day was January 7, 2026 (+32.31%) and its worst was March 30, 2026 (-42.13%). The stock moved 10% or more in a single session 32 times. It opened at least 5% above the previous day's high 2 times.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.
Find more stocks like FBLG with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.